Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

NCT ID: NCT02571049

Last Updated: 2019-02-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2016-05-31

Brief Summary

Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.

Detailed Description

Pilot study to compare the proportion of subjects experiencing pain freedom at 60 minutes post-treatment between headache treated with Strength A of DFN-11 and Strength B of DFN-11

Conditions

Rapidly Escalating Migraine

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Sumatriptan 3 mg then 6 mg

DFN-11 (sumatriptan, 3 mg) and placebo first then two DFN-11 injections

Group Type: EXPERIMENTAL

DFN-11

Intervention Type: DRUG

Sumatriptan 3 mg versus 6 mg

Sumatriptan 6 mg then 3 mg

Two DFN-11 (sumatriptan, 3 mg) injections first then DFN-11 injection and placebo

Group Type: EXPERIMENTAL

DFN-11

Intervention Type: DRUG

Sumatriptan 3 mg versus 6 mg

Interventions

DFN-11

Sumatriptan 3 mg versus 6 mg

Intervention Type: DRUG

Other Intervention Names

Sumatriptan succinate injection

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of episodic migraine, with or without aura for at least 1 year prior to screening

2. Experience an average of 2 to 8 migraines per month for the past 12 months of which approximately 75% or more rapidly escalate to moderate or severe pain within 2 hours of onset

3. Females must:

• be practicing an effective method of birth control (e.g. prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], or male partner sterilization) before entry and throughout the study, or
• be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), or
• be postmenopausal (spontaneous amenorrhea for at least 1 year)

4. Females of child-bearing potential must have a negative urine pregnancy test at screening

5. Able and willing to read and comprehend written instructions and complete the electronic diary information required by the protocol

6. Must have internet access to complete daily headache diary

Exclusion Criteria

1. Inability to distinguish migraine from other primary headaches

2. Experiences headache of any kind at a frequency greater than or equal to 15 days per month

3. Chronic opioid therapy (> 10 days in the 30 days prior to screening)

4. Current treatment with monoamine oxidase A (MAO-A) inhibitors or use within 4 weeks before randomization

5. Hemiplegic or basilar migraine

6. History, symptoms or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes

7. Uncontrolled hypertension (screening systolic/diastolic blood pressure > 140/90 mmHg in 2 out of 3 readings)

8. History of epilepsy or conditions associated, which in the opinion of the Investigator, increase the likelihood of present day seizure

9. History (within 2 years) of drug or alcohol abuse as defined by DSM-IV-TR criteria.

10. Systemic disease, which in the opinion of the Investigator, would contraindicate participation

11. History of a neurological or psychiatric condition, which in the opinion of the Investigator would contraindicate participation

12. Pregnant or lactating women

13. Have taken any investigational medication within 30 days before randomization, or are scheduled to receive an investigational drug

14. Subjects with a positive urine drug screen for recreational drugs or marijuana (whether legal or not) or for prescription drugs not explained by stated concomitant medications

15. Clinical laboratory or electrocardiogram (ECG) abnormality that in the opinion of the Investigator would endanger the subject or interfere with the study conduct. If the results of the clinical laboratory or ECG are outside of normal reference range the subject may still be enrolled but only if these findings are determined to be not clinically significant by the Investigator. This determination must be recorded in the subject's source document prior to enrolment.

16. Fridericia's corrected QT (QTcF) interval greater than 450 msec

17. Severe renal impairment (creatinine > 2 mg/dl)

18. Serum total bilirubin > 2.0 mg/dL

19. Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal

20. Subjects who in the opinion of the investigator experience rebound headache from caffeine usage

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dr. Reddy's Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Clinvest

Springfield, Missouri, United States

Countries

United States

References

Cady RK, Munjal S, Cady RJ, Manley HR, Brand-Schieber E. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. J Headache Pain. 2017 Dec;18(1):17. doi: 10.1186/s10194-016-0717-7. Epub 2017 Feb 7.

Reference Type: RESULT

PMID: 28176235 (View on PubMed)

Other Identifiers

DFN-11-CD-006

Identifier Type: -

Identifier Source: org_study_id